Evidence map›Paper›PMID 37078875›Full record

ArticleMicrobiology spectrum2023

Marta Palau, Estela Muñoz, Muriel F Gusta, Nieves Larrosa, Xavier Gomis, Joan Gilabert, Benito Almirante, Victor Puntes, Robert Texidó, Joan Gavaldà

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Effect of Biosynthesized Gold and Silver Nanoparticles UsingAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Mapping the knowledge landscape ofFrontiers in cellular and infection microbiology · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Evaluating Anti-Journal of pharmacy & bioallied sciences · 2024
    Article
  12. Article
  13. Article
  14. Medicine and pharmacy reports · 2024
    Article
  15. Article
  16. Review
  17. Antimicrobial resistance ofFrontiers in microbiology · 2024
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Marta Palau *Antibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID 0000-0002-4567-9868
Estela Muñoz *Antibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID 0000-0002-6693-4987
Muriel F GustaInstitut Català de Nanociència i Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, Barcelona, Spain.
Nieves LarrosaSpanish Network for Research in Infectious Diseases (REIPI RD19/0016), Instituto de Salud Carlos III, Madrid, Spain.
Xavier GomisAntibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Joan GilabertTractivus SL, Barcelona, Spain.
Benito AlmiranteAntibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Victor PuntesInstitut Català de Nanociència i Nanotecnologia (ICN2), CSIC, The Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, Barcelona, Spain.
Robert TexidóGrup d'Enginyeria de Materials (GEMAT), Universitat Ramón Llull, Barcelona, Spain.
Joan Gavaldà *Antibiotic Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID 0000-0002-9829-3141
Instituto de Salud Carlos III · ESInstitució Catalana de Recerca i Estudis Avançats · ESInstitut Català de Nanociència i Nanotecnologia · ESUniversitat Ramon Llull · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In view of the current increase and spread of antimicrobial resistance (AMR), there is an urgent need to find new strategies to combat it. This study had two aims. First, we synthesized highly monodispersed silver nanoparticles (AgNPs) of approximately 17 nm, and we functionalized them with mercaptopoly(ethylene glycol) carboxylic acid (mPEG-COOH) and amikacin (AK). Second, we evaluated the antibacterial activity of this treatment (AgNPs_mPEG_AK) alone and in combination with hyperthermia against planktonic and biofilm-growing strains. AgNPs, AgNPs_mPEG, and AgNPs_mPEG_AK were characterized using a suite of spectroscopy and microscopy methods. Susceptibility to these treatments and AK was determined after 24 h and over time against 12 clinical multidrug-resistant (MDR)/extensively drug-resistant (XDR) isolates of Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The efficacy of the treatments alone and in combination with hyperthermia (1, 2, and 3 pulses at 41°C to 42°C for 15 min) was tested against the same planktonic strains using quantitative culture and against one P. aeruginosa strain growing on silicone disks using confocal laser scanning microscopy. The susceptibility studies showed that AgNPs_mPEG_AK was 10-fold more effective than AK alone, and bactericidal efficacy after 4, 8, 24, or 48 h was observed against 100% of the tested strains. The combination of AgNPs_mPEG_AK and hyperthermia eradicated 75% of the planktonic strains and exhibited significant reductions in biofilm formation by P. aeruginosa in comparison with the other treatments tested, except for AgNPs_mPEG_AK without hyperthermia. In conclusion, the combination of AgNPs_mPEG_AK and hyperthermia may be a promising therapy against MDR/XDR and biofilm-producing strains.

Indexed as

Hyperthermia, InducedMetal NanoparticlesAmikacinAnti-Bacterial AgentsBiofilmsPolyethylene GlycolsSilverAmikacinAnti-Bacterial Agentsmonomethoxypolyethylene glycolPolyethylene GlycolsSilveramikacinantibacterial activitybiofilmshyperthermiaMDR/XDRsilver nanoparticles

Identifiers

PMID37078875
PMCPMC10269648
OpenAlexW4366463323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.